Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Chiesi gets rights to Santhera's ophthalmic drug Raxone

Executive Summary

Santhera Pharmaceuticals AG licensed Chiesi Farmaceutici SPA exclusive worldwide rights (excluding the US and Canada) to develop, commercialize, and distribute its Raxone (idebenone) for Leber's hereditary optic neuropathy (LHON) and all other ophthalmic indications.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes M&A Option
    • R&D and Marketing (Licensing)

Related Companies